TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling

Related Experiment Video

Updated: Jul 3, 2026

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

Atsuo Kurata1, Ryohei Katayama, Toshiki Watanabe

  • 1Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo 135-8550, Japan.

Cancer Science
|July 12, 2008
PubMed

Insights

Tumor suppressor candidate 4 (TUSC4/NPRL2) interacts with 3-phosphoinositide-dependent protein kinase-1 (PDK1) to inhibit its activity. TUSC4/NPRL2 regulates cell proliferation and enhances cancer drug sensitivity.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Cancer Research

Background:

  • 3-Phosphoinositide-dependent protein kinase-1 (PDK1) is crucial for cell proliferation and survival.
  • PDK1 is activated by Src-mediated phosphorylation, contributing to its constitutive activity.

Purpose of the Study:

  • To identify novel regulators of PDK1 activity.
  • To investigate the role of TUSC4/NPRL2 in the Src/PDK1 signaling pathway.

Main Methods:

  • E. coli-based two-hybrid screening to identify PDK1-interacting proteins.
  • In vitro and cellular assays to assess the effect of TUSC4/NPRL2 on PDK1 phosphorylation and activity.
  • siRNA-mediated gene silencing and ectopic expression to study TUSC4/NPRL2 function.
  • Analysis of downstream signaling pathways (Akt, p70S6K) and cancer cell drug sensitivity.

Main Results:

  • TUSC4/NPRL2 forms a complex with PDK1, specifically through its N-terminal 133 amino acids.
  • TUSC4/NPRL2 suppresses Src-dependent tyrosine phosphorylation and activation of PDK1.
  • Down-regulation of TUSC4/NPRL2 promotes cell proliferation.
  • Ectopic TUSC4/NPRL2 expression inactivates PDK1 downstream signaling and increases sensitivity to anticancer drugs.

Conclusions:

  • TUSC4/NPRL2 is a novel regulator of the Src/PDK1 signaling pathway.
  • TUSC4/NPRL2 plays a role in controlling cell proliferation and sensitivity to chemotherapy.
  • Targeting the TUSC4/NPRL2-PDK1 interaction may offer therapeutic strategies for cancer treatment.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...